64 related articles for article (PubMed ID: 9784409)
1. Intracellular expression of the anti-erbB-2 sFv N29 fails to accomplish efficient target modulation.
Grim JE; Siegal GP; Alvarez RD; Curiel DT
Biochem Biophys Res Commun; 1998 Sep; 250(3):699-703. PubMed ID: 9784409
[TBL] [Abstract][Full Text] [Related]
2. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2.
Wright M; Grim J; Deshane J; Kim M; Strong TV; Siegal GP; Curiel DT
Gene Ther; 1997 Apr; 4(4):317-22. PubMed ID: 9176517
[TBL] [Abstract][Full Text] [Related]
3. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody.
Deshane J; Cabrera G; Grim JE; Siegal GP; Pike J; Alvarez RD; Curiel DT
Gynecol Oncol; 1995 Oct; 59(1):8-14. PubMed ID: 7557620
[TBL] [Abstract][Full Text] [Related]
4. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines.
Deshane J; Loechel F; Conry RM; Siegal GP; King CR; Curiel DT
Gene Ther; 1994 Sep; 1(5):332-7. PubMed ID: 7584099
[TBL] [Abstract][Full Text] [Related]
5. Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis.
Deshane J; Grim J; Loechel S; Siegal GP; Alvarez RD; Curiel DT
Cancer Gene Ther; 1996; 3(2):89-98. PubMed ID: 8729907
[TBL] [Abstract][Full Text] [Related]
6. Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity.
Barnes MN; Deshane JS; Siegal GP; Alvarez RD; Curiel DT
Clin Cancer Res; 1996 Jul; 2(7):1089-95. PubMed ID: 9816272
[TBL] [Abstract][Full Text] [Related]
7. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes.
Altenschmidt U; Kahl R; Moritz D; Schnierle BS; Gerstmayer B; Wels W; Groner B
Clin Cancer Res; 1996 Jun; 2(6):1001-8. PubMed ID: 9816261
[TBL] [Abstract][Full Text] [Related]
8. Down-modulation of the CXCR4 co-receptor by intracellular expression of a single chain variable fragment (SFv) inhibits HIV-1 entry into primary human brain microvascular endothelial cells and post-mitotic neurons.
Mukhtar M; Acheampong E; Khan MA; Bouhamdan M; Pomerantz RJ
Brain Res Mol Brain Res; 2005 Apr; 135(1-2):48-57. PubMed ID: 15857668
[TBL] [Abstract][Full Text] [Related]
9. Enhanced intracellular stability of sFv-Fc fusion intrabodies.
Strube RW; Chen SY
Methods; 2004 Oct; 34(2):179-83. PubMed ID: 15312671
[TBL] [Abstract][Full Text] [Related]
10. [Expression and Characterization of Single-chain Fv-Fc Fusion Protein against Human P185(erbB2)].
Xie ZG; Guo N; Shi M; Feng JN; Yu M; Sun YX; Shen BF
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Apr; 35(4):371-4. PubMed ID: 12673393
[TBL] [Abstract][Full Text] [Related]
11. Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction.
Turatti F; Figini M; Balladore E; Alberti P; Casalini P; Marks JD; Canevari S; Mezzanzanica D
J Immunother; 2007 Oct; 30(7):684-93. PubMed ID: 17893561
[TBL] [Abstract][Full Text] [Related]
12. erbB-2 knockout employing an intracellular single-chain antibody (sFv) accomplishes specific toxicity in erbB-2-expressing lung cancer cells.
Grim J; Deshane J; Feng M; Lieber A; Kay M; Curiel DT
Am J Respir Cell Mol Biol; 1996 Sep; 15(3):348-54. PubMed ID: 8810638
[TBL] [Abstract][Full Text] [Related]
13. Antineoplastic effect of anti-erbB-2 intrabody is not correlated with scFv affinity for its target.
Arafat W; Gómez-Navarro J; Xiang J; Siegal GP; Alvarez RD; Curiel DT
Cancer Gene Ther; 2000 Sep; 7(9):1250-6. PubMed ID: 11023197
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of HIV-1 infection by down-regulation of the CXCR4 co-receptor using an intracellular single chain variable fragment against CXCR4.
BouHamdan M; Strayer DS; Wei D; Mukhtar M; Duan LX; Hoxie J; Pomerantz RJ
Gene Ther; 2001 Mar; 8(5):408-18. PubMed ID: 11313818
[TBL] [Abstract][Full Text] [Related]
15. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies.
BouHamdan M; Kulkosky J; Duan LX; Pomerantz RJ
J Hum Virol; 2000; 3(1):6-15. PubMed ID: 10774802
[TBL] [Abstract][Full Text] [Related]
17. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial.
Alvarez RD; Barnes MN; Gomez-Navarro J; Wang M; Strong TV; Arafat W; Arani RB; Johnson MR; Roberts BL; Siegal GP; Curiel DT
Clin Cancer Res; 2000 Aug; 6(8):3081-7. PubMed ID: 10955787
[TBL] [Abstract][Full Text] [Related]
18. Intracellular single-chain antibody against hepatitis B virus core protein inhibits the replication of hepatitis B virus in cultured cells.
Yamamoto M; Hayashi N; Takehara T; Ueda K; Mita E; Tatsumi T; Sasaki Y; Kasahara A; Hori M
Hepatology; 1999 Jul; 30(1):300-7. PubMed ID: 10385671
[TBL] [Abstract][Full Text] [Related]
19. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
20. Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3.
Jia LT; Zhang LH; Yu CJ; Zhao J; Xu YM; Gui JH; Jin M; Ji ZL; Wen WH; Wang CJ; Chen SY; Yang AG
Cancer Res; 2003 Jun; 63(12):3257-62. PubMed ID: 12810656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
